Fisher & Paykel Demonstrates Humidified Nasal High Flow System for Delivering Respiratory Support at MEDICA 2021
By HospiMedica International staff writers Posted on 18 Nov 2021 |
Fisher & Paykel Healthcare (F&P; Auckland, New Zealand) demonstrated its Airvo 2 nasal high flow (NHF) system that is designed to deliver proven respiratory support at MEDICA 2021.
The F&P Respiratory Care Continuum illustrates the breadth of respiratory therapies patients may require when in need of respiratory assistance. NHF is recognized by the WHO for treatment of patients with COVID-19. NHF has been used as respiratory support throughout the pandemic and its use on COVID-19 patients has been observed to keep patients off mechanical ventilation and help them stay off, lower the rate of mortality, and reduce length of stay.
The Airvo 2 is an integrated solution for delivering Optiflow high flow therapy. F&P’s leading humidification technology allows the Airvo 2 to comfortably provide high flows of humidified air (with supplemental oxygen if required) to spontaneously breathing patients, through the unique series of Optiflow interfaces. It features three temperature settings, including 37°C (body temperature pressure saturated for a normothermic patient) i.e. optimal humidity. An integrated flow generator delivers a wide flow range 10 - 60 L/min for adult patients and 2 - 25 L/min for pediatric patients, taking patients from the most acute environments (ICU and ED) to the home.
It also features F&P’s Evaqua technology which reduces the formation of mobile condensate. Oxygen can be added from a wall supply or cylinder. Its in-built ultrasonic oxygen analyzer requires no calibration, service or replacement. No separate temperature probes or heater-wire adapters are required. The Airvo 2, with its wide range of accessories, provides versatility, mobility and convenience. A compact system with a built-in flow generator means there’s no need for a noisy, heavy air compressor in order to use the Airvo 2 for transport. A suitable UPS can be added, and the Airvo 2 is ready to go.
Related Links:
Fisher & Paykel Healthcare
Latest COVID-19 News
- Low-Cost System Detects SARS-CoV-2 Virus in Hospital Air Using High-Tech Bubbles
- World's First Inhalable COVID-19 Vaccine Approved in China
- COVID-19 Vaccine Patch Fights SARS-CoV-2 Variants Better than Needles
- Blood Viscosity Testing Can Predict Risk of Death in Hospitalized COVID-19 Patients
- ‘Covid Computer’ Uses AI to Detect COVID-19 from Chest CT Scans
- MRI Lung-Imaging Technique Shows Cause of Long-COVID Symptoms
- Chest CT Scans of COVID-19 Patients Could Help Distinguish Between SARS-CoV-2 Variants
- Specialized MRI Detects Lung Abnormalities in Non-Hospitalized Long COVID Patients
- AI Algorithm Identifies Hospitalized Patients at Highest Risk of Dying From COVID-19
- Sweat Sensor Detects Key Biomarkers That Provide Early Warning of COVID-19 and Flu
- Study Assesses Impact of COVID-19 on Ventilation/Perfusion Scintigraphy
- CT Imaging Study Finds Vaccination Reduces Risk of COVID-19 Associated Pulmonary Embolism
- Third Day in Hospital a ‘Tipping Point’ in Severity of COVID-19 Pneumonia
- Longer Interval Between COVID-19 Vaccines Generates Up to Nine Times as Many Antibodies
- AI Model for Monitoring COVID-19 Predicts Mortality Within First 30 Days of Admission
- AI Predicts COVID Prognosis at Near-Expert Level Based Off CT Scans